Clinical study about the hypotensive effect and the inhibitory effect on the elevatin of uric acid level irbesartan and trichlormethiazide in the essential hypertension patients

agoya Medical Association0 个研究点目标入组 100 人开始时间: 2014年6月25日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Essential hypertensive patients who have been taking ARB except irbesartan (IrbetanR) and losartan and concomitantly with trichlormethiazide (FluitranR) 1 mg, and have not changed these medications at least for 8 weeks,
•whose systolic blood pressure (BP) or diastolic BP at baseline is >=130 or >=80 mmHg respectively and also who signed on informed consent to participate in this study.

•Patients with severe hypertension (diastolic BP >=120 mmHg), secondary or malignant hypertension. Patients with recent history of myocardial infarction or stroke within 6 months.
•Patients with severe hepatic dysfunction (AST >=100 IU/L or ALT >=100 IU/L or bilirubin >=2.5 mg/dL),or with renal dysfunction (serum creatinine >=2.0 mg/dL or e-GFR<30 mL/min/1.73 m2), or type 1 diabetes mellitus, or poorly controlled type 2 diabetes mellitus.
•Patients with drug or alcohol abuse. Patients who are pregnant or breastfeeding.
•Patients under participation in other clinical trials.
•Patients with history of hypersensitivity to irbesartan (IrbetanR) and trichlormethiazide (FluitranR)
•Patients who took some concomitant drugs prohibited during the previous 8 weeks before the start of study.
•Patients who are deemed ineligible by investigator.

发起方

agoya Medical Association